I'm LongbridgeAI, I can summarize articles.MicuRx Pharmaceuticals announced that its new drug application for injectable Contizolam Sodium has been accepted by the National Medical Products Administration. This drug is a new oxazolidinone antibacterial developed independently by the company, aimed at treating complicated skin and soft tissue infections based on the successful application of Contizolam tablets. The company has completed the relevant Phase III clinical trials and achieved the primary efficacy endpoints
According to the Zhitong Finance APP, MicuRx (688373.SH) announced that it recently received the "Acceptance Notice" issued by the National Medical Products Administration, indicating that the company's new drug application (NDA) for injectable Contizolam Sodium has been accepted.
Contizolam Tablets and MRX-4 are the company's independently developed class 1 antibacterial new drugs with global intellectual property rights. Injectable Contizolam Sodium is a water-soluble prodrug of Contizolam developed by the company based on in-depth analysis and scientific exploration of Contizolam. Since Contizolam Tablets have been approved in China for the treatment of complicated skin and soft tissue infections, in order to expedite the approval of injectable Contizolam Sodium in China, the company has conducted a Phase III clinical trial in China, comparing intravenous infusion of Contizolam Sodium to oral administration of Contizolam Tablets for the treatment of adult patients with complicated skin and soft tissue infections. This clinical trial has been successfully completed and achieved its primary efficacy endpoint